ICU Medical (ICUI)
(Delayed Data from NSDQ)
$101.77 USD
+1.06 (1.05%)
Updated May 7, 2024 04:00 PM ET
After-Market: $101.76 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$101.77 USD
+1.06 (1.05%)
Updated May 7, 2024 04:00 PM ET
After-Market: $101.76 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth B Momentum B VGM
Zacks News
ICU Medical (ICUI) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 48.44% and 13.53%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: ICU Medical (ICUI) Q3 Earnings Expected to Decline
by Zacks Equity Research
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ICU Medical (ICUI) Looks Good: Stock Adds 8.1% in Session
by Zacks Equity Research
ICU Medical (ICUI) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Medical Products Stock Earnings on Aug 10: CGC, SDGR & More
by Trina Mukherjee
Despite the impact of the pandemic on the second quarter, Medical Product companies have shown strength on the back of huge adoption of COVID-19 related healthcare-support products and services.
Analysts Estimate ICU Medical (ICUI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate ICU Medical (ICUI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Gibraltar Industries, PJT Partners, ICU Medical, eXp World and Innovative Industrial Properties
by Zacks Equity Research
Zacks.com featured highlights include: Gibraltar Industries, PJT Partners, ICU Medical, eXp World and Innovative Industrial Properties
Buy These 5 Stocks on New Analyst Coverage Amid Coronavirus
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Zacks.com featured highlights include: eXp, American States Water, ICU Medical, Universal Technical Institute and SFL
by Zacks Equity Research
Zacks.com featured highlights include: eXp, American States Water, ICU Medical, Universal Technical Institute and SFL
New Analyst Coverage Brings 5 Stocks in Focus Amid Coronavirus
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
ResMed (RMD) Grows on SaaS Capabilities Amid Rising Expenses
by Zacks Equity Research
Within SaaS, ResMed (RMD) registers growing momentum in the Brightree service portfolio.
Steady Global Growth, Product Launches Aid Hill-Rom Business
by Zacks Equity Research
Hill-Rom (HRC) holds an encouraging 2022 outlook in terms of product launches.
ICU Medical (ICUI) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 19.75% and 6.79%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
ICU Medical (ICUI) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 1.85% and 6.10%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate ICU Medical (ICUI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for August 30th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Moving Average Crossover Alert: ICU Medical
by Zacks Equity Research
ICU Medical, Inc. (ICUI) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
ICU Medical (ICUI) Misses Q2 Earnings Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of -4.78% and 1.32%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: ICU Medical (ICUI) Q2 Earnings Expected to Decline
by Zacks Equity Research
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ICU Medical (ICUI) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
ICU Medical (ICUI) delivered earnings and revenue surprises of 18.35% and 4.13%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: ICU Medical (ICUI) Q1 Earnings Expected to Decline
by Zacks Equity Research
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CONMED (CNMD) Beats on Q1 Earnings, Raises '19 Guidance
by Zacks Equity Research
Higher revenues, solid segmental performance and strong adjusted gross margins benefit CONMED's (CNMD) Q1 earnings. However, high long-term debt remains a concern.
Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Higher revenues, growth in APAC and strong operating margin benefit Baxter's (BAX) Q1 earnings. However, weak performance at Medication Delivery and Clinical Nutrition remains a concern.
Edwards Lifesciences (EW) Q1 Earnings Beat, EPS View Raised
by Zacks Equity Research
Edwards Lifesciences (EW) gains on strong segmental contributions in Q1.
Boston Scientific (BSX) Misses Q1 Earnings, Tightens EPS View
by Zacks Equity Research
Boston Scientific (BSX) is investing in new technologies and the global markets, which in turn, aids the uptick in sales across its most geographies in Q1.